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Abstract: 
 
The study presented herein constitutes an extensive investigation of constituents in Hydrastis 
canadensis L. (Ranunculaceae) leaves. It describes the isolation and identification of two 
previously unknown compounds, 3,4-dimethoxy-2-(methoxycarbonyl)benzoic acid (1) and 
3,5,3′-trihydroxy-7,4′-dimethoxy-6,8-C-dimethyl-flavone (2), along with the known compounds 
(±)-chilenine (3), (2R)-5,4′-dihydroxy-6-C-methyl-7-methoxy-flavanone (4), 5,4′-dihydroxy-6,8-
di-C-methyl-7-methoxy-flavanone (5), noroxyhydrastinine (6), oxyhydrastinine (7) and 4′,5′-
dimethoxy-4-methyl-3′-oxo-(1,2,5,6-tetrahydro-4H-1,3-dioxolo-[4′,5′:4,5]-benzo[1,2-e]-1,2-
oxazocin)-2-spiro-1′-phtalan (8). Compounds 3–8 have been reported from other sources, but 
this is the first report of their presence in H. canadensis extracts. A mass spectrometry based 
assay was employed to demonstrate bacterial efflux pump inhibitory activity against 
Staphylococcus aureus for 2, with an IC50 value of 180 ± 6 μM. This activity in addition to that 
of other bioactive compounds such as flavonoids and alkaloids, may explain the purported 
efficacy of H. canadensis for treatment of bacterial infections. Finally, this report includes high 
mass accuracy fragmentation spectra for all compounds investigated herein which were uploaded 
into the Global Natural Products Social molecular networking library and can be used to 
facilitate their future identification in H. canadensis or other botanicals. 
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Article: 
 
1. Introduction 
 
The medicinal plant Hydrastis canadensis L. (Ranunculaceae) has a long history of use for the 
treatment of infections. Native Americans, particularly the Cherokee, used goldenseal roots to 
treat skin and eye infections, while other populations have used goldenseal tonics to treat 
gastrointestinal irritation (Foster, 2000). H. canadensis roots have been extensively profiled (Le 
et al., 2013, Bharathi et al., 2012, McNamara et al., 2004), although only a few reports have 
described the composition of H. canadensis leaves (Junio et al., 2011, Douglas et al., 2010). H. 
canadensis has been of recent interest due to its ability to inhibit the growth of pathogenic 
bacteria, including Staphylococcus aureus (Cech et al., 2012). This activity was originally 
attributed to the antimicrobial alkaloid berberine and to other alkaloids that the plant contains 
(Knight, 1999, Scazzocchio et al., 2001, Hwang et al., 2003). Recently, it has been shown that 
the activity of H. canadensis leaves is more complex. Three flavonoids, sideroxylin, 6-desmethyl 
sideroxylin and 8-desmethyl sideroxylin (Junio et al., 2011) were shown to synergistically 
enhance the antimicrobial activity of goldenseal alkaloids. These flavonoids act as bacterial 
efflux pump inhibitors, facilitating accumulation of berberine within bacterial cells and thereby 
reducing the necessary quantity of berberine (or other alkaloids) to achieve antimicrobial activity 
(Junio et al., 2011). 
 
Botanicals are chemically complex and contain many compounds that may possess diverse 
structures and biological activities. On the basis of the previously reported interesting biological 
activity of H. canadensis leaves, we endeavored to conduct more in-depth chemical profiling of 
this botanical. With these studies, we sought to identify efflux pump inhibitors from H. 
canadensis, and to generate a more comprehensive profile of chemical compounds in this 
botanical than has previously been published. 
 
2. Results and discussion 
 
2.1. Structures of isolated compounds 
 
Investigation of H. canadensis leaves led to isolation of two new compounds, 3,4-dimethoxy-2-
(methoxycarbonyl)benzoic acid (1) and 3,5,3′-trihydroxy-7,4′-dimethoxy-6,8-C-dimethyl-
flavone (2), together with six additional compounds (3–8) that are known but new to H. 
canadensis (Fig. 1). (±)-Chilenine (3), an isoindolobenzazepine alkaloid, was previously reported 
from Berberis enpetrifolia (Fajardo et al., 1982); flavonones (2R)-5,4′-dihydroxy-6-C-methyl-7-
methoxy-flavanone (4) and 5,4′-dihydroxy-6,8-di-C-methyl-7-methoxy-flavanone (5) were 
isolated from leaf wax of Callistemon coccineus (Wollenweber et al., 2000); and the 
isoquinolone derivatives noroxyhydrastinine (6) and oxyhydrastinine (7) were obtained from 
Thalictrum minus and Hypecoum erectum, respectively (Doskotch et al., 1969, Zhang et al., 
1995). Compound 8, 4′,5′-dimethoxy-4-methyl-3′-oxo-(1,2,5,6-tetrahydro-4H-1,3-dioxolo-
[4′,5′:4,5]-benzo[1,2-e]-1,2-oxazocin)-2-spiro-1′-phtalan, was reported previously as a product of 
β-hydrastine-N-oxide under reflux conditions (Klötzer and Oberhänsli, 1955). Given that β-
hydrastine is an abundant constituent of H. canadensis (Le et al., 2014), it is possible that 
compound 8 is an isolation artifact and not a constituent of H. canadensis. Additionally, nine 
compounds known to be constituents of H. canadensis were also isolated. These include 
berberine (9) (Qiu et al., 2008), (−)-canadine (10) (Malhotra et al., 1989), sideroxylin (11), 6-
desmethyl-sideroxylin (12), 8-desmethyl-sideroxylin (13) (Junio et al., 2011), β-hydrastine (14) 
(Seger et al., 2004), (−)-8-oxocanadine (15), 8-oxotetrahydrothalifendine (16) (Pinho et al., 
1992), and oxyberberine (17) (Singh et al., 2010). The structures of these known compounds 
were determined by comparing their spectroscopic data with those reported in the literature. 
 
 
Fig. 1. Structures of compounds 1–8, which are reported for the first time in this report as 
constituents of goldenseal (Hydrastis canadensis). The configuration at locations with asterisks 
are unknown. 
 
Compound 1 was obtained as white amorphous powder. High resolving power electrospray 
ionization mass spectrometry (HRESIMS) analysis indicated an ion at m/z 241.0702 
[M+H]+ (calcd for C11H13O6+, 241.0707), suggesting six degrees of unsaturation. The NMR 
spectral data (Table 1) allowed the assignment of two aromatic protons (δH = 6.98 and 7.87) and 
three methoxy groups (δH = 3.87, 3.94 and 3.95). The HMBC analysis allowed correlation of two 
of the methoxy groups (δH = 3.87 and 3.95) with carbon C-3 and C-4 (δC = 145.9 and 157.4), 
respectively. Additionally, the correlation between H-5 (δH = 6.98) and the resonance 
at δC = 145.9 (C-3), and between H-6 (δH = 7.87) with δC = 157.4 (C-4) supported the placement 
of the methoxy groups. The HMBC correlations between H-5 (δH = 6.98) and δC = 118.7, and H-
6 (δH = 7.87) with δC = 131.8 supported the assignment of the carboxylic group at C-1 and 
the methoxycarbonyl group at C-2 (Fig. 2). Therefore, the structure of 1 was established as 3,4-
dimethoxy-2-(methoxycarbonyl)benzoic acid. 
 
Table 1. 1H (400 MHz) and 13C (100 MHz) NMR spectroscopic dataa for 3,4-dimethoxy-2-
(methoxycarbonyl)benzoic acid (1). 
Position δC δH, m (J in Hz) HMBCb 
1 118.7   
2 131.8   
3 145.9   
4 157.4   
5 112.2 6.98, d (8.8) C-1, C-3 
6 128.4 7.87, d (8.8) C-2, C-4, C-1a 
1a 168.6   
2a 167.5   
3-OCH3 61.9 3.87, s C-3 
4-OCH3 56.3 3.95, s C-4 
2a-OCH3 53.0 3.94, s C-2a 
a 1H and 13C chemical shifts with reference to CDCl3 (δH = 7.26 ppm) and CDCl3 (δC = 77.16 ppm), respectively. 
b HMBC correlations are from the proton stated to the indicated carbon. 
 
 
Fig. 2. HMBC correlations of 1. 
 
Compound 2, obtained as a yellow amorphous powder, showed in HRESIMS an ion at 
m/z359.1129 [M+H]+ (calcd for C19H19O7, 359.1125). The UV maxima absorption bands at 
λmax377, 346 and 258 nm were suggestive of a flavone skeleton, given that the absorbance 
maxima of flavonols are generally at longer wavelengths (350–385 nm) (Tsimogiannis et al., 
2007). The 1H NMR data (Table 2) indicated the presence of two aromatic methoxy groups 
(δH = 3.80 and 4.00), two C-methyls (δH = 2.41 and 2.23), and three aromatic protons (δH = 7.87, 
7.82 and 7.00). Analysis of the 13C NMR spectrum (Table 2) showed the presence of a α,β-
unsaturated carbonyl (δC = 175.9) and a signal at δC = 136.2, which together with the proton 
signals of the aromatic rings correspond to a flavonol skeleton. HMBC correlations of 7-OCH3 
(δH = 3.80), 6-CH3 (δH = 2.23) and 8-CH3 (δH = 2.41) methyl protons with C-7 (δC = 163.0) 
support the position of the substituents in ring A (Fig. 3). In addition, the methoxy and hydroxy 
group in the B ring were assigned based on the correlation between 4′-OCH3 (δH = 4.00) with the 
C-4′ (δC = 148.4), and the correlations between 5′-H (δH = 7.00) with C-1′ (δC = 124.6) and C-3′ 
(δC = 145.8) in the HMBC spectrum. Additionally, the HMBC correlations between 2′-H 
(δH = 7.82) and 6′-H (δH = 7.87) with C-2 (δC = 145.8) supported the connectivity of ring B to C-
2 (ring C) (Fig. S10). On the basis of this evidence, the compound was determined to be 3,5,3′-
trihydroxy-7,4′-dimethoxy-6,8-C-dimethyl-flavone. 
 
Reisolation of known compounds from botanical extracts is a common problem when seeking to 
identify novel compounds from botanicals such as H. canadensis. To facilitate future 
identification of compounds 1–17 in botanical mixtures, tandem high resolving power 
electrospray ionization mass spectrometry (HRESIMS-MS) was employed to collect 
fragmentation spectra of all seventeen compounds in both the positive ion mode (Table S1) and 
the negative ion mode (Tables S2). Notably, these fragmentation spectra were collected with 
high mass accuracy (<10 ppm), enabling the confirmation of molecular formulae of many of the 
fragments. An example of such a high resolution fragment spectrum is provided in Fig. 4 for 2. 
High mass accuracy measurements of fragmentation data enable assignment of molecular 
formulae not just for the intact molecule, but also for its fragments. The fragments with m/z of 
344.0890, 329.0654, and 316.0941 represent rearrangements and losses from the C ring, and 
those with m/z of 301.0708 and 259.0965 represent a partial loss of the C ring with bonds formed 
with the hydroxyl group at carbon 3. The fragments with m/z of 195.0653 and 179.0347 
represent the remaining A ring along with the ketone at carbon 4. An additional fragmentation 
spectrum of berberine (9), the most abundant alkaloid present in goldenseal (Le et al., 2014) can 
be found as Supporting information (Fig. S26). Spectra for 2, berberine, and the remaining H. 
canadensis compounds identified herein were uploaded into the Global Natural Product Social 
molecular networking library to facilitate identification of these compounds or their structural 
analogs by other researchers (Wang et al., 2016). Fragment masses can also be found in Tables 
S1 and S2. 
 
2.2. Efflux pump inhibitory activity of isolated compounds 
 
The two new compounds isolated as part of this study [3,4-dimethoxy-2-
(methoxycarbonyl)benzoic acid (1) and 3,5,3′-trihydroxy-7,4′-dimethoxy-6,8-C-dimethyl-
flavone (2)], as well as the compounds 4 and 16 were tested for biological activity. Specifically, 
a mass spectrometry based assay was employed to evaluate the ability of these compounds to 
inhibit efflux of an efflux pump substrate (ethidium bromide) from S. aureus cells (Brown et al., 
2015). The rationale for evaluating efflux pump inhibitory activity is that drug efflux constitutes 
a major form of antibiotic resistance in bacteria (Kaatz, 2005). Thus, compounds that prevent 
efflux of toxins from cells have the potential of contributing to antimicrobial activity. Efflux 
inhibitory activity against S. aureus is particularly relevant given that this pathogen is 
responsible for approximately 50% of all skin infections, and H. canadensis is traditionally used 
in the treatment of such infections (McCaig et al., 2006). 
 
Compound 2 demonstrated moderate inhibitory activity of efflux from S. aureus with an IC50 
value of 180 ± 6 μM. Compounds 1, 4 and 16 were inactive. Fig. 5 shows the raw experimental 
data evaluating the efflux pump inhibitory activities of compounds 1, 2, and the positive control, 
carbonyl cyanide m-chloro phenylhydrazone (CCCP), which had an IC50 of 270 ± 50 μM. The 
data shown are relative quantities (as measured by mass spectrometric peak area) of ethidium ion 
in the spent bacterial media after exposure to an increasing amount of the test compound or 
control. As demonstrated for both CCCP and 2, when efflux is blocked, the quantity of ethidium 
present in the media decreases (Fig. 5). Ethidium concentration remains high regardless of 
concentration for the compound that does not possess efflux inhibitory activity (Compounds 1, 4 
and 16). 
 
 
Fig. 5. Efflux pump inhibition assay data for 3,4-dimethoxy-2-(methoxycarbonyl)benzoic acid 
(1) and 3,5,3′-trihydroxy-7,4′-dimethoxy-6,8-C-dimethyl-flavone (2). The positive control for 
this assay is carbonyl cyanide m-chloro-phenylhydrazone (CCCP), a compound that inhibits 
efflux by collapsing the proton motive force across the cell membrane (Hopfer et al., 1967). Each 
data point is the mean of triplicate measurements from separate bacterial cultures (biological 
replicates) and error bars represent standard error of the mean. 
 
3. Experimental 
 
3.1. General experimental procedures 
 
Optical rotations at the sodium D-line wavelength of pure compounds were measured with a 
Rudolph Research Autopol (II) Polarimeter. 1D and 2D NMR spectra were recorded using a 
JEOL ECS-400 NMR spectrometer equipped with a high sensitivity JEOL Royal probe operating 
at 400 MHz for 1H and 100 MHz for 13C, or an Agilent 700 MHz NMR spectrometer (Agilent 
Technologies, Inc., Santa Clara, CA, USA) equipped with a cryoprope, operating at 700 MHz 
for 1H and 175 MHz for 13C. Chemical shifts are reported as δ values (ppm), and coupling 
constants (J) were measured in Hz. HRESIMS was performed on a Thermo LTQ Orbitrap XL 
mass spectrometer equipped with an electrospray ionization source. HPLC was carried out using 
a Varian ProStar HPLC system equipped with ProStar 210 pumps and a ProStar 335 photodiode 
array detector (PDA), with data collected and analyzed using Galaxie Chromatography 
Workstation software (version 1.9.3.2). For preparative HPLC, a Phenomenex Gemini-NX C18 
Column (5 μm; 250 mm × 21.2 mm) was used at a 21 mL/min flow rate. Flash chromatography 
was performed on a Teledyne ISCO CombiFlash®Rf using 80 g or 120 g RediSep® RF 
SilicaColumn (35–70 μm particle size) and 12 g RediSep®Rf Gold HP Silica Columns (20–40 
μm particle size, Teledyne ISCO, Lincoln, NE, USA), and monitored by UV and evaporative 
light-scattering detectors. UV spectra were measured with a ProStar 335 photodiode array UV 
detector (PDA) and the reported λmax values were collected from the spectra for relevant 
compounds eluting from the HPLC. All other reagents and solvents were obtained from Fisher 
Scientific and were used without further purification. 
 
3.2. Plant material 
 
H. canadensis L. (Ranunculaceae) was collected in Hendersonville, North Carolina (NC, N 
3524.2770, W 08220.9930, 702.4 m elevation), in July 2013. The plants were cultivated in their 
native environment, a hardwood forest understory. A voucher specimen (NCU583414) was 
deposited in the University of North Carolina Herbarium, Chapel Hill, NC and the identity was 
verified by herbarium director Dr. Alan S. Weakley. 
 
3.3. Extraction and isolation 
 
The isolation scheme is provided as Supporting information (Fig. S1). Batches of dried H. 
canadensis plant were pulverized into fine powder using a commercial coffee grinder (Kitchen 
Aid). H. canadensis powder was percolated in MeOH overnight, and the MeOH extract was 
concentrated in vacuo and subjected to liquid-liquid partition, as described previously (Junio et 
al., 2011). This concentrated extract was defatted by partitioning between 10% aqueous MeOH 
and hexane (1:1), and the aqueous MeOH fraction was partitioned further between 
EtOAc:MeOH:H2O (4:1:5). The organic layer was washed with 1% saline solution to remove 
tannins. 
 
The first stage of normal-phase flash chromatography (120 g silica gel column) was conducted 
with a Hex/CHCl3/MeOH gradient, yielding 8 primary fractions (FI–FVIII). Fraction FII, FIII 
and FIV were subjected to a second stage of normal-phase flash chromatography (80 g silica gel 
column) with a Hex/EtOAc/MeOH gradient to give 5 (FII1–FII5), 3 (FIII1–FIII3) and 6 (FIV1–
FIV6) subfractions, respectively. 
 
The compounds were purified using reversed-phase preparative HPLC with a Phenomenex 
Gemini-NX C18 column at a 21 mL/min flow rate. Fraction FII2 (32.5 mg) (eluents A: H2O 
0.1% formic acid, B: CH3CN, gradient: B 45% at time 0, B 75% at time 20 min, B 100% at time 
25 min) yielded the compounds (2R)-5,4′-dihydroxy-6-C-methyl-7-methoxy-flavanone (4; 
1.5 mg), 5,4′-dihydroxy-6,8-di-C-methyl-7-methoxy-flavanone (5; 0.7 mg), and 3,5,3′-
trihydroxy-7,4′-dimethoxy-6,8-C-dimethyl-flavone (2; 0.6 mg). 
 
Fractions FII3 (30.1 mg), FII4 (7.3 mg) and FIII1 (26.9 mg) were purified (eluents A: H2O 0.1% 
formic acid, B: CH3CN, gradient: B 35% at time 0, B 90% at time 27 min, B 100% at time 30 
min) to obtain oxyhydrastinine (7; 2.0 mg), chilenine (3; 0.8 mg) for the first fraction, 
noroxyhydrastinine (6; 0.9 mg) for the second fraction, and (2R)-5,4′-dihydroxy-6-C-methyl-7-
methoxy-flavanone (4; 0.5 mg) for the last fraction. 
 
Fraction FIV3 (96.3 mg) (eluents A: H2O 0.1% formic acid, B: CH3CN, gradient: B 30% at time 
0, B 90% at time 20 min, B 100% at time 22 min) and fraction FIV5 (42.3 mg) (eluents A: H2O 
0.1% formic acid, B: CH3CN, gradient: B 30% at time 0, B 65% at time 20 min, B 100% at time 
22 min) yielded chilenine (3; 1.0 mg) and 3,4-dimethoxy-2-(methoxycarbonyl) benzoic acid (1; 
1.2 mg), respectively. 
 
3,4-dimethoxy-2-(methoxycarbonyl)benzoic acid (1): white powder; UV λmax 208 and 259 nm; 1H 
(400 MHz) and 13C NMR (100 MHz) data see Table 1. HRESIMS m/z241.07021 [M+H]+ (calcd 
for C11H13O6 241.0707). 
 
3,5,3′-trihydroxy-7,4′-dimethoxy-6,8-C-dimethyl-flavone (2): yellow powder; UV λmax 217, 258, 
346 and 377 nm; 1H (700 MHz) and 13C NMR (175 MHz) data see Table 2. HRESIMS m/z 
359.11287 [M+H]+ (calcd for C19H19O7 359.1125). 
 
(±)-chilenine (3): white powder; [α]D25 = 0.0 (c 0.22, MeOH); UV λmax 215 and 318 nm; 1H 
NMR (400 MHz, CDCl3) δ: 7.36 (1H, d, J = 8.4 Hz, H-11), 7.05 (1H, d, J = 8.4 Hz, H-12), 6.71 
(1H, s, H-1), 6.66 (1H, s, H-4), 5.95 (2H, dd, J = 7.2, 1.2 Hz, OCH2O), 4.26 (1H, m, H-6), 3.99 
(3H, s, OCH3-9), 3.87 (3H, s, OCH3-10), 3.56 (1H, m, H-5), 3.30 (1H, m, H-6), 3.11 (1H, m, H-
5); 13C NMR (100 MHz, CDCl3) δ: 199.8 (C-14), 166.7 (C-8), 154.5 (C-10), 151.6 (C-3), 147.1 
(C-2), 146.7 (C-9), 133.7 (C-4a), 131.7 (C-12a), 130.7 (C-14a), 124.1 (C-9a), 120.6 (C-12), 
116.3 (C-11), 109.4 (C-4), 109.2 (C-1), 101.9 (OCH2O), 94.9 (C-13), 62.6 (OCH3-9), 56.6 
(OCH3-10), 38.9 (C-6), 30.7 (C-5); HRESIMS m/z 384.10751 [M+H]+ (calcd for C20H18NO7 
384.1078). 
 
(2R)-5,4′-dihydroxy-6-C-methyl-7-methoxy-flavanone (4): yellow oil; [α]D25 =−7.33 (c 0.3, 
MeOH); UV λmax 216, 291 and 338 nm; 1H NMR (400 MHz, CDCl3) δ: 12.1 (OH-5), 7.35 (2H, 
d, J = 8.4 Hz, H-2′ and H-6′), 6.89 (1H, d, J = 8.4 Hz, H-3′ and H-5′), 6.07 (1H, s, H-8), 5.35 
(1H, dd, J = 13.2, 2.8, H-2), 3.83 (3H, s, OCH3-7), 3.09 (1H, dd, J = 17.2, 13.2 Hz, H-3), 2.77 
(1H, dd, J = 17.2, 2.8 Hz, H-3), 2.01 (1H, s, CH3-6); 13C NMR (100 MHz, CDCl3) δ: 196.2 (C-
4), 165.8 (C-7), 161.3 (C-9), 160.5 (C-5), 156.2 (C-4′), 130.9 (C-1′), 128.1 (C-2′ and C-6′), 115.8 
(C-3′ and C-5′), 106.1 (C-6), 102.9 (C-10), 90.9 (C-8), 79.2 (C-2), 55.9 (OCH3-7), 43.5 (C-3), 
7.0 (CH3-6); HRESIMS m/z 301.10709 [M+H]+ (calcd for C17H17O5301.10780). 
 
5,4′-dihydroxy-6,8-di-C-methyl-7-methoxy-flavanone (5): yellow oil; [α]D25 =−6.86 (c 0.12, 
MeOH); UV λmax 192, 222, 282 and 361 nm; 1H NMR (400 MHz, CDCl3) δ: 12.0 (OH-5), 7.35 
(2H, d, J = 8.4 Hz, H-2′ and H-6′), 6.89 (1H, d, J = 8.4 Hz, H-3′ and H-5′), 5.34 (1H, dd, 
J = 12.8, 2.8 Hz, H-2), 3.74 (3H, s, OCH3-7), 3.06 (1H, dd, J = 17.2, 12.8 Hz, H-3), 2.83 (1H, 
dd, J = 17.2, 2.8 Hz, H-3), 2.10 (3H, s, CH3-6), 2.07 (3H, s, CH3-8); 13C NMR (100 MHz, 
CDCl3) δ: 197.7 (C-4), 162.5 (C-7), 160.2 (C-5), 158.1 (C-4′), 156.4 (C-9), 131.5 (C-1′), 127.8 
(C-2′ and C-6′), 119.5 (C-8),116.2 (C-3′ and C-5′), 108.2 (C-6), 104.0 (C-10), 79.7 (C-2), 63.5 
(OCH3-7), 40.7 (C-3), 9.9 (CH3-8), 9.3 (CH3-6); HRESIMS m/z 315.12292 [M+H]+ (calcd for 
C18H19O5 315.1227). 
 
Noroxyhydrastinine (6): yellow powder; UV λmax 222, 261 and 306 nm; 1H NMR (400 MHz, 
CDCl3) δ: 7.50 (1H, s, H-8), 6.66 (1H, s, H-5), 6.01 (2H, s, OCH2O), 3.53 (2H, t, J = 6.8, 6.4 Hz, 
H-3), 2.91 (1H, t, J = 6.8, 6.4 Hz, H-4); 13C NMR (100 MHz, CDCl3) δ: 166.5 (C-1), 151.5 (C-
6), 147.2 (C-7), 135.0 (C-5a), 121.5 (C-8a), 108.0 (C-8), 107.5 (C-5), 101.8 (OCH2O), 40.4 (C-
3), 28.3 (C-4); HRESIMS m/z 192.06526 [M+H]+ (calcd for C10H10NO3192.0655). 
 
Oxyhydrastinine (7): yellow pale powder; UV λmax 222, 264 and 304 nm; 1H NMR (400 MHz, 
CDCl3) δ: 7.54 (1H, s, H-8), 6.61 (1H, s, H-5), 5.99 (2H, s, OCH2O), 3.51 (2H, t, J = 6.8, 6.8 Hz, 
H-3), 2.90 (1H, t, J = 6.8, 6.8 Hz, H-4), 3.13 (3H, s, N-CH3); 13C NMR (100 MHz, CDCl3) δ: 
164.7 (C-1), 150.4 (C-6), 146.9 (C-7), 133.6 (C-5a), 123.5 (C-8a), 108.3 (C-8), 107.0 (C-5), 
101.6 (OCH2O), 48.3 (C-3), 35.3 (N-CH3), 28.1 (C-4); HRESIMS m/z 206.08127 [M+H]+ (calcd 
for C11H12NO3 206.08117). 
 
4′,5′-dimethoxy-4-methyl-3′-oxo-(1,2,5,6-tetrahydro-4H-1,3-dioxolo-[4′,5′:4,5]-benzo[1,2-e]-
1,2-oxazocin)-2-spiro-1′-phtalan (8): yellow pale powder; [α]D25 =+4.8 (c 0.17, MeOH); 
UV λmax 218, 245 and 300 nm; 1H NMR (400 MHz, CDCl3) δ: 7.04 (2H, d, J = 8.4 Hz, H-6′), 
6.75 (1H, s, H-7), 6.36 (1H, s, H-11), 6.33 (1H, d, J = 8.4 Hz, H-7′), 6.00 and 5.94 (2H, s, 
OCH2O), 4.28 (1H, m, H-1), 4.11 (3H, s, OCH3-4′), 3.88 (3H, s, OCH3-5′), 3.35 (1H, m, H-6), 
3.07 (2H, m, H-5), 2.76 (3H, s, N-CH3), 2.70 (2H, m, H-1 and H-6); 13C NMR (100 MHz, 
CDCl3) δ: 165.8 (C-3′), 154.0 (C-5′), 148.1 (C-4′), 146.9 (C-8), 145.4 (C-10), 138.9 (C-7′a), 
135.1 (C-7a), 126.9 (C-11a), 119.7 (C-7′), 119.1 (C-4′a), 118.0 (C-6′), 112.6 (C-11), 111.1 (C-7), 
109.5 (C-2), 101.2 (C-9), 62.5 (OCH3-4′), 62.1 (C-5), 56.8 (OCH3-5′), 49.2 (N-CH3), 40.6 (C-1), 
36.6 (C-6); HRESIMS m/z 400.1375 [M+H]+ (calcd for C21H22NO7 400.1391). 
 
3.4. Collection of HRESIMS fragmentation data 
 
Each of the 17 isolated compounds were suspended in MeOH at either 1 mg/mL or 0.1 mg/mL 
and subjected to ultraperformance liquid chromatography tandem mass spectrometry (UPLC-
MS/MS) analysis via a Waters Acquity UPLC with an Acquity UPLC column (BEH C18, 1.7 μm, 
2.1 mm × 50 mm, Waters Corporation, Milford, MA) coupled to a Thermo Q Exactive Plus 
orbitrap mass spectrometer with heated electrospray ionization (Thermo Fisher Scientific, MA, 
USA). The compounds were eluted from the column at a flow rate of 0.3 mL/min using a binary 
solvent system with A consisting of water with 0.1% formic acid additive and solvent B 
consisting of acetonitrile with 0.1% formic acid additive. The gradient was as follows: 95:5 
(A:B) from 0 to 1 min, increasing to 90:10 (A:B) from 1 to 2 min, 80:20 (A:B) from 2 to 3 min, 
60:40 (A:B) from 3 to 4 min, 70:30 (A:B) from 4 to 5 min, 0:100 (A:B) from 5 to 6 min and held 
from 6 to 7 min, 95:5 (A:B) from 7 to 8 min and held from 8 to 9 min. Duplicate analyses of 
each sample were conducted in both positive and negative polarities using the following settings: 
spray voltage, 3.7 kV; capillary temperature, 350 °C; sheath gas, 25; auxiliary gas, 5; S-lens RF 
level, 50. Each compound was chosen for fragmentation via high energy collision-induced 
dissociation (HCD, normalized collision energy set to 50) from an inclusion list for both 
polarities. To determine the average mass accuracy of the product ions, the fragmentation spectra 
of 2 was compared to theoretical fragments produced by ACD MS fragmenter (Advanced 
Chemistry Development, Inc., Toronto, Canada). The resulting accurate mass of the predicted 
chemical formulas and hypothetical structures were matched with experimental data and were 
within 10 ppm mass error (Fig. 4). 
 
3.5. Efflux pump inhibition assay 
 
Four of the isolated compounds (1, 2, 4 and 16) were of sufficient purity (91%, 98%, 95% and 
100%, respectively, by LC-UV) and quantity for evaluation via an efflux pump inhibition assay, 
as previously described (Brown et al., 2015). The assay was modified from the previously 
reported method in the chromatographic gradient, in some of the mass spectrometric conditions, 
and in the use S. aureus strain SA1199 (Kaatz and Seo, 1995). 
 
The gradient was as follows: 95:5 (A:B) from 0 to 1 min, increasing to 0:100 (A:B) from 1 to 
3.5 min, held from 3.5 to 9.5 min, 95:5 (A:B) from 9.5 to 10 min. A divert valve was utilized, 
with the valve set to waste from 0 to 1.5 min and to inject from 1.5 to 10 min. The mass 
spectrometric analyses were conducted under the following conditions: spray voltage, 3 kV; 
capillary temperature, 250 °C; vaporizer temperature, 40 °C; sheath gas, 40; aux gas, 30; tube 
lens offset, −112. Mass spectral dose–response data were analyzed with SigmaPlot (Systat 
Software, San Jose, CA) to calculate IC50 values for each of the active compounds. 
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